This information was published on 2024-05-01T18:16:34 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2445309 |
| (220) |
24 Apr 2024
|
| (300) |
US, 25 Oct 2023, 98238958
|
| (511) (510) |
Class 5
Pharmaceutical and biological preparations for treating tenosynovial giant cell tumor (TGCT), giant cell tumor of the tendon sheath (GCT-TS), and pigmented villonodular synovitis (PVNS); Pharmaceutical and biological preparations for use in orthopedics, rheumatology, oncology, neurology, immunology, and hematology; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing diseases, disorders, and conditions affecting the musculoskeletal system, central nervous system, immune system, and blood; Pharmaceutical and biological preparations for treating tumors, sarcomas, tenosynovial giant cell tumors, graft versus host disease (GVHD), Parkinson's disease, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS); Therapeutic agents, namely, kinase inhibitors |
| (540) | ROMVIMZA |
| (550) | Word |
| (730) |
Deciphera Pharmaceuticals, LLC
|
| (750) |
AJ Park
|
Find out more about publications on the About page.